Clinical Trial Update: The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating camrelizumab plus apatinib as second-line therapy for advanced pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Pancreatic Cancer | Phase 2 | Status: UNKNOWN